Aimovig

Novartis Europharm Limited,Vista Building,Elm Park, Merrion Road,Dublin 4,Ireland🇪🇺 European Union

EMA Page

Authorised Date: Jul 26, 2018
Approval ID: 945144fd06412e6c
Products: 2 listed
Opinion Adopted: N/A

Overview Summary

Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. Aimovig contains the active substance erenumab.

Therapeutic & Classification

Therapeutic Indication

### Therapeutic indication Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

Therapeutic Area (MeSH)

N/A

ATC Code

N02CD01

ATC Item

erenumab

Pharmacotherapeutic Group

Analgesics

Active Substances

Active Substance (Summary)

erenumab

INN / Common Names

N/A

Active Substance Details

Substance	CAS	Monograph
erenumab	N/A	依瑞奈尤单抗

Quick Info

Approval ID945144fd06412e6c

Product NumberN/A

StatusAuthorised

Authorised DateJul 26, 2018

Opinion AdoptedN/A

Revision #N/A

Names & Aliases

EMA Name

Aimovig

Medicine Name

Aimovig

Aliases

N/A

Regulatory Flags

Orphan medicineUnknown

Generic medicineUnknown

BiosimilarUnknown

Conditional approvalUnknown

Exceptional circumstancesUnknown

Accelerated assessmentUnknown

Additional monitoringUnknown

Advanced therapyUnknown

Source Links

EMA Source

No risk management plan link.

Back to EMA Approvals